Servier Chooses Tripos as Chemistry Partner in Search for Drugs
News Sep 08, 2005
Tripos, Inc. and Servier have announced that they will work together to identify potential drugs. Servier identified and subsequently validated therapeutic compounds from Tripos' LeadQuest® compound collection.
Based on these results, Servier has chosen to partner with Tripos to further design and synthesize compounds for potential drug development. Tripos will employ its ChemSpace® and LeadHopping® proprietary technologies and integrated knowledge-driven chemistry processes to identify additional chemistries against the same targets.
Tripos' ChemSpace technology is used to identify similar but distinct chemical entities, while its LeadHopping technology helps scientists navigate the patent space.
"Servier has earned an impressive reputation for research, and to be chosen as their partner is an honor for our Tripos team," said Dr. Mark Allen, senior vice president and managing director of Tripos Discovery Research, Ltd.
He adds, "By applying our proprietary chemistry processes, Servier will be able to identify potential leads much sooner, therefore accelerating the research process. We hope the success we generate through this drug discovery project will lay the foundation for future Tripos and Servier partnerships and developments."
Modified Form of Botox Could Replace Opioids as Treatment for Chronic PainNews
A modified form of botulinum toxin gives long-lasting pain relief in mice without adverse effects and, in time, could replace opioid drugs as a safe and effective way of treating chronic pain, according to new research.READ MORE
Key Ingredient in Diabetes Drug Modified to Improve Side EffectsNews
Improved medications for Type 2 diabetes are one step closer thanks to a new discovery reported this week. By modifying the key ingredient in current diabetes drugs, the researchers produced a compound that was effective for hyperglycemia in animal trials, yet without the most problematic side effects of current drugs.READ MORE
Tackling Cancer at Ground Zero: Designer Molecule Inhibits Protein TargetNews
A new molecule designed by University of Adelaide researchers shows great promise for future treatment of many cancers. The new molecule successfully targets a protein that plays a major role in the growth of most cancers.READ MORE